UBS Group AG Purchases 54,580 Shares of Urogen Pharma $URGN

UBS Group AG boosted its position in Urogen Pharma (NASDAQ:URGN) by 30.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 235,040 shares of the company’s stock after purchasing an additional 54,580 shares during the period. UBS Group AG’s holdings in Urogen Pharma were worth $5,505,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Paradigm Biocapital Advisors LP bought a new position in Urogen Pharma in the third quarter worth approximately $84,111,000. Soleus Capital Management L.P. bought a new position in Urogen Pharma in the 2nd quarter worth $29,934,000. SG Americas Securities LLC increased its stake in Urogen Pharma by 19.0% in the 4th quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock worth $32,264,000 after buying an additional 220,264 shares in the last quarter. TCG Crossover Management LLC purchased a new stake in Urogen Pharma in the 3rd quarter worth $14,311,000. Finally, Orbimed Advisors LLC raised its holdings in Urogen Pharma by 44.0% during the third quarter. Orbimed Advisors LLC now owns 689,000 shares of the company’s stock valued at $13,746,000 after acquiring an additional 210,600 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Up 6.9%

Urogen Pharma stock opened at $30.22 on Thursday. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $32.37. The firm’s fifty day moving average is $22.30 and its 200 day moving average is $22.25. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -10.99 and a beta of 1.58.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million. On average, equities research analysts anticipate that Urogen Pharma will post -0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Oppenheimer boosted their price target on Urogen Pharma from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. D. Boral Capital restated a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a research note on Tuesday, March 31st. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Urogen Pharma in a report on Monday. Finally, Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.67.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.